MRNA-1647 not checked

Moderna

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
9 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).”In the company’s words, NCT05683457 on ClinicalTrials.gov
Tested for
Cytomegalovirus Infection
Main trialPhase 2
“The main purpose of the study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV prophylactic treatment (for example, letermovir) on Day 100 post-HCT through Month 9 post-HCT.”In the company’s words, NCT05683457 on ClinicalTrials.gov

Other drugs for Cytomegalovirus Infection

All 3 drugs for Cytomegalovirus Infection

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 6 Mar 2027 A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
Phase 3Terminated 4 Nov 2025 A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
Phase 2Completed 4 Jan 2023 Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
Phase 2Completed 19 Jan 2026 A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
Phase 2Withdrawn 14 Feb 2027 A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
Phase 1/2Completed 12 May 2026 A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
Phase 1Completed 28 Oct 2020 Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
Phase 1Completed 10 Aug 2023 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
Phase 1Completed 27 Feb 2026 A Study of Modified mRNA Vaccines in Healthy Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow MRNA-1647

Following is part of Solo: you see every change to MRNA-1647 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in